Practical Guide to YO-01027 (Dibenzazepine, DBZ) γ-secretase Inhibitor

What This Product Solves

YO-01027, also known as dibenzazepine (DBZ), is a dipeptidic γ-secretase inhibitor designed to block the proteolytic cleavage of type I membrane proteins, notably within the Notch signaling pathway and amyloid precursor protein-like (APPL) substrates. This compound is relevant for researchers aiming to dissect Notch pathway contributions to cell fate decisions, particularly in models of breast cancer stem cell activity regulation and intestinal adenoma epithelial cell proliferation inhibition. By preventing γ-secretase-mediated activation of Notch signaling, YO-01027 provides a precise tool to investigate differentiation processes, such as goblet cell induction, and to assess effects on cellular proliferation in oncogenic or developmental contexts. It is not indicated for studies requiring continuous aqueous dosing or where long-term compound stability in solution is essential.

Protocol Parameters

• assay: APPL cleavage inhibition | value_with_unit: IC₅₀ = 2.6 nM | applicability: Quantifying γ-secretase inhibitory potency in APPL-overexpressing cell systems | rationale: Supports targeted inhibition of amyloid precursor protein-like cleavage events | source_type: product_spec [product_url]
• assay: Notch cleavage inhibition | value_with_unit: IC₅₀ = 2.9 nM | applicability: Use in cell or animal models requiring robust Notch pathway blockade | rationale: Enables dose-dependent Notch signaling pathway suppression | source_type: product_spec [product_url]
• assay: In vivo dosing (mouse model) | value_with_unit: 0–30 μmol/kg, intraperitoneally, once daily for 5 days | applicability: Animal studies targeting epithelial cell differentiation or proliferation | rationale: Empirically derived dosing window for effective Notch inhibition in murine systems | source_type: product_spec [product_url]
• assay: Stock solution preparation | value_with_unit: ≥23.17 mg/mL in DMSO; ≥4.13 mg/mL in ethanol (with gentle warming and ultrasonication); insoluble in water | applicability: Preparation of concentrated stocks for in vitro or in vivo dosing | rationale: Ensures reliable solubility and compatibility with typical delivery vehicles | source_type: product_spec [product_url]
• assay: In vitro working concentration | value_with_unit: ~10 μM (workflow recommendation) | applicability: Initial screening and pathway inhibition in cultured cells | rationale: Aligns with reported experimental conditions for Notch pathway studies | source_type: workflow_recommendation

Workflow Setup and QC Checklist

• Compound handling: Store YO-01027 as a solid at -20°C. Protect from repeated freeze-thaw cycles to preserve potency. Use solutions promptly after preparation; do not store working solutions long-term.
• Stock preparation: Dissolve YO-01027 in DMSO (≥23.17 mg/mL) or ethanol (≥4.13 mg/mL) with gentle warming and ultrasonication. Confirm complete dissolution visually; filter sterilize if needed for cell culture.
• Vehicle controls: Match DMSO or ethanol concentrations in control wells or animals to account for solvent effects. Keep final solvent concentration ≤0.1% (v/v) in cell-based assays to minimize cytotoxicity.
• Dose selection: For initial in vitro studies, start at 10 μM with serial dilutions to determine the minimal effective dose for target pathway inhibition.
• Quality control: Validate γ-secretase inhibition by monitoring downstream Notch targets (e.g., Hes1 expression) or APPL cleavage products. Include positive and negative controls in all experiments.
• Batch documentation: Record lot number, preparation date, and storage conditions for all YO-01027 stocks to ensure reproducibility.

Common Failure Modes and Fixes

• Incomplete solubilization: If YO-01027 does not dissolve fully in DMSO or ethanol, apply gentle warming and ultrasonication in short intervals. Avoid water as a solvent, as the product is insoluble.
• Loss of inhibitory activity: Do not store YO-01027 solutions for extended periods. Always prepare fresh working solutions before use. Discard any solutions showing precipitate or discoloration.
• Vehicle toxicity: If cells show unexpected toxicity, verify that final DMSO/ethanol concentrations are within acceptable limits and adjust vehicle-only controls accordingly.
• Inconsistent dosing in animal models: Use calibrated syringes for intraperitoneal injections, and ensure uniform mixing of YO-01027 in the dosing vehicle prior to administration.
• Insufficient pathway inhibition: Confirm batch potency and titrate up to the maximum recommended dose (30 μmol/kg in mice) if target inhibition is suboptimal, monitoring for any off-target effects or toxicity.

Scope and Limitations

YO-01027 is formulated for research use in models where acute and specific inhibition of γ-secretase is required, particularly in studies of Notch signaling pathway interference, breast cancer stem cell activity regulation, and intestinal adenoma epithelial cell proliferation inhibition. Its solubility profile restricts usage to DMSO or ethanol-based formulations, precluding direct aqueous dosing or studies demanding water-soluble delivery. YO-01027 is not suitable for experiments requiring chronic solution storage, as stability is not assured beyond immediate use. The compound’s effects are limited to systems expressing target substrates and presenilin complexes sensitive to γ-secretase inhibition; off-target mechanisms have not been characterized in the absence of direct evidence.

Conclusion

YO-01027 (Dibenzazepine, DBZ) provides researchers with a well-characterized γ-secretase inhibitor suitable for precise modulation of Notch and APPL cleavage in vitro and in vivo. When handled according to recommended protocols, it enables reproducible assessment of Notch signaling pathway inhibition and downstream phenotypes, such as goblet cell induction and epithelial proliferation arrest. For complete product details and technical support, consult the YO-01027 (Dibenzazepine, DBZ) γ-secretase inhibitor page at APExBIO.